...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >STEM CELL AND REGENERATIVE MEDICINE GLOBAL CONFERENCE (SCRGC) 2016 (AUGUST 23-24, 2016-GYEONGGI-DO, KOREA)
【24h】

STEM CELL AND REGENERATIVE MEDICINE GLOBAL CONFERENCE (SCRGC) 2016 (AUGUST 23-24, 2016-GYEONGGI-DO, KOREA)

机译:2016年干细胞和再生医学全球会议(SCRGC)(2016年8月23日至24日,韩国庆基道)

获取原文
获取原文并翻译 | 示例

摘要

In its third edition, the Stem Cell and Regenerative Medicine Global Conference (SCRGC) organized by the Global Stem Cell & Regenerative Medicine Acceleration Center (GSRAC) was focused on breaking barriers to accelerate the pace of innovation and development of the regenerative medicine industry. GSRAC is both a think tank and a global network of key opinion leaders from the public and the private sectors. GSRAC was commissioned in 2011 by the Ministry of Health and Welfare (MOHW) of Korea. GSRAC's primary mission is to enable and accelerate the delivery of innovative technologies to patients who are affected by currently untreatable diseases. This goal is notably achieved by resolving hurdles in the field of regenerative medicine. With a total of 30 speakers and panelists from 8 different countries and more than 400 attendees from an array of institutions including hospitals, clinics, biotechnology companies, pharmaceutical companies, scientists, as well as policy makers, the 2-day SCRGC highlighted critical challenges and paths to resolving them in policy and regulatory, and industrial-scale manufacturing of gene-based and cell-based therapies, comprising plenary lectures and sessions covering strategic policy, regulatory, reimbursement and business development, and business of manufacturing, and production technologies. Several of these presentations are summarized in this report.
机译:在第三版中,由全球干细胞与再生医学加速中心(GSRAC)组织的全球干细胞与再生医学会议(SCRGC)着重于突破障碍,以加快再生医学行业的创新与发展步伐。 GSRAC既是智囊团,也是公共和私营部门主要意见领袖的全球网络。 GSRAC是由韩国卫生和福利部(MOHW)于2011年委托进行的。 GSRAC的主要任务是使创新技术能够并加速向目前无法治愈的疾病患者提供服务。解决再生医学领域的障碍尤其可以实现这一目标。历时2天的SCRGC吸引了来自8个不同国家的30位演讲者和小组成员,来自医院,诊所,生物技术公司,制药公司,科学家以及政策制定者等机构的400多名与会者参加了此次会议。解决这些问题的途径,包括政策和法规,以及基于基因和细胞疗法的工业规模生产,包括全体演讲和会议,内容涉及战略政策,法规,报销和业务发展以及制造和生产技术业务。本报告中总结了其中一些演示。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号